These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28624005)

  • 1. Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: Classification tree analysis applying capsule and septum.
    Min JH; Kim YK; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Ahn HS
    Eur J Radiol; 2017 Jul; 92():1-10. PubMed ID: 28624005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.
    Choi SY; Kim YK; Min JH; Kang TW; Jeong WK; Ahn S; Won H
    Eur Radiol; 2018 Jun; 28(6):2549-2560. PubMed ID: 29335868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.
    Park HJ; Jang KM; Kang TW; Song KD; Kim SH; Kim YK; Cha DI; Kim J; Goo J
    Eur Radiol; 2016 Sep; 26(9):3102-11. PubMed ID: 26634931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
    Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
    Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
    J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scirrhous hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging: emphasis on the differentiation of intrahepatic cholangiocarcinoma.
    Park MJ; Kim YK; Park HJ; Hwang J; Lee WJ
    J Comput Assist Tomogr; 2013; 37(6):872-81. PubMed ID: 24270108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma.
    Park HJ; Kim YK; Park MJ; Lee WJ
    Abdom Imaging; 2013 Aug; 38(4):793-801. PubMed ID: 22829097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.
    Hwang J; Kim YK; Min JH; Choi SY; Jeong WK; Hong SS; Kim HJ; Ahn S; Ahn HS
    Eur Radiol; 2017 Nov; 27(11):4581-4590. PubMed ID: 28500365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.
    Chong YS; Kim YK; Lee MW; Kim SH; Lee WJ; Rhim HC; Lee SJ
    Clin Radiol; 2012 Aug; 67(8):766-73. PubMed ID: 22425613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features of hepatic sarcomatous carcinoma on computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
    Gu KW; Kim YK; Min JH; Ha SY; Jeong WK
    Abdom Radiol (NY); 2017 May; 42(5):1424-1433. PubMed ID: 28078380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.
    Han D; Li Y; He X; Zhang J; Zhou Y; Zhang J; Zhang L
    Quant Imaging Med Surg; 2023 Oct; 13(10):7156-7169. PubMed ID: 37869332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size.
    Ni T; Shang XS; Wang WT; Hu XX; Zeng MS; Rao SX
    Br J Radiol; 2018 Jul; 91(1088):20180017. PubMed ID: 29791202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in Cirrhotic Livers May Share Similar Enhancement Patterns at Multiphase Dynamic MR Imaging.
    Huang B; Wu L; Lu XY; Xu F; Liu CF; Shen WF; Jia NY; Cheng HY; Yang YF; Shen F
    Radiology; 2016 Oct; 281(1):150-7. PubMed ID: 27077381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
    Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
    Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.